Biomarkers for monitoring antiangiogenic therapy

被引：25

作者：

Bhatt, Rupal S.

Seth, Pankaj

Sukhatme, Vikas P.

机构：

[1] Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, Boston, MA 02215 USA

[2] Beth Israel Deaconess Med Ctr, Dept Med, Div Nephrol, Boston, MA 02215 USA

[3] Beth Israel Deaconess Med Ctr, Dept Med, Div Interdisciplinary Med, Boston, MA 02215 USA

[4] Beth Israel Deaconess Med Ctr, Dept Med, Div Biotechnol, Boston, MA 02215 USA

来源：

CLINICAL CANCER RESEARCH | 2007年 / 13卷 / 02期

关键词：

D O I：

10.1158/1078-0432.CCR-06-1922

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

A variety of antiangiogenic agents are currently available for the treatment of renal cell carcinoma. With these exciting new therapeutic agents comes the challenge of elucidating useful biomarkers to monitor patients receiving these therapies. Although many patients benefit from antiangiogenic therapies, it is often by achieving stability of their disease. Thus, development of noninvasive biomarkers of disease response and relapse is a crucial objective to aid in the management of patients. The current technologies being explored in this field include circulating plasma proteins, cells, and nucleic acids and novel imaging techniques. Surrogate markers of angiogenesis could help with selecting patients for therapy, determining optimal dosing of therapy, deciding whether to change therapy, and assessing appropriate salvage therapy.

引用

页码：777S / 780S

页数：4

共 18 条

[1] Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: Implications for use as a surrogate marker of antiangiogenic activity [J].